SpyGlass Pharma (SGP) Cash & Equivalents (2024 - 2026)
SpyGlass Pharma (SGP) posted quarterly Cash & Equivalents of $96.4 million for Q4 2025, up 492.32% year-over-year from $16.3 million in Q4 2024, and up 492.32% quarter-over-quarter from $16.3 million in Q4 2024.
SpyGlass Pharma (SGP) Cash & Equivalents (2024 - 2026) Analysis & Trends
SpyGlass Pharma (SGP) has reported Cash & Equivalents for 2 consecutive years, with $96.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash & Equivalents rose 492.32% year-over-year to $96.4 million; the TTM figure through Dec 2025 stood at $96.4 million (up 492.32% YoY), while the FY2025 annual figure was $96.4 million, up 492.32% from the prior year.
- Cash & Equivalents rose to $96.4 million in Q4 2025 per SGP's latest filing, from $16.3 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $96.4 million in Q4 2025 and bottomed at $16.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | SpyGlass Pharma | 876.29 Mn | 876.29 Mn | - | 223.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 223.14 Mn |
| Dec 31, 2025 | 96.36 Mn |
| Dec 31, 2024 | 16.27 Mn |